Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) — Analysis Summary
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) has a market cap of $42.46B with year-over-year revenue growth of +4.3%. Net margin stands at 8.2%. The stock trades at a P/E ratio of 60.1.
Key Takeaways
- Revenue changed +4.3% year-over-year
- Net margin of 8.2%
- P/E ratio of 60.1
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, TEVA posted revenue growth of +4.3% and trades at a P/E of 60.1.
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.88x — current liabilities exceed current assets
Net income fell 49.9% vs the prior period.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
32,842
Headquarters
TEL AVIV
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.34
Dividend Yield
0.93%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.